cyrilzakka/clinical-trials huggingface dataset:
Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak

During the COVID-19 pandemic, the Egyptian government issued movement restrictions and placed areas into quarantine to reduce the spread of the disease. In addition, individuals were encouraged to adopt personal protective measures, such as social isolation , increasing personal hygiene and wearing protective face masks. Information regarding the COVID 19 virus and protective measures is found on social media and ministry of health website and a number of the Egyptian population are keeping track of them .Public Awareness play a major rule in reducing the spread of COVID 19 so in this study a survey is done to measure the awareness of the Egyptian population toward COVID 19 , their knowledge and attitude and their adherence to preventive measures.It also measures the change of their behavior during the beginning of the outbreak and after a few months of the outbreak in Egypt.

Detailed Description:

The survey will enroll as many individuals of the Egyptian population as possible in the survey portion of the study - The number of participates have no limitations, at least 700 participants.

The survey will be enrolled in online google form, face to face interview(this will be reduced to encourage social isolation) \& semi-structured telephone interviews if possible.

The research procedures:

An online survey link will include questions regarding the awareness of the Egyptian population , their knowledge , attitudes and behaviour during covid-19 outbreak.and also a comparison of their behaviour among different time periods of the outbreak Face to face and semi-structured interviews if possible: For those Egyptian citizens who state that they would like to participate in an interview, a random sample will be contacted.

Inclusion Criteria:

Egyptian population of any age group

Exclusion Criteria:

none

Eligibility Criteria:
Inclusion Criteria:

Egyptian population of different age groups

Exclusion Criteria:

none
Positioning of the Tibial Cut in Unicompartmental Medial Knee Replacement by Using Patient Specific Cutting Guides.

Unicompartmental knee replacements are performed to treat osteoarthritis or osteonecrosis of the knee especially when it affects only the medial femoro-tibial compartment. To place the prosthesis, bone removal is necessary. The orientations of the bony cuts directly influence the position of the different elements of the prosthesis and the limb alignment. It is known that good positioning of the prosthesis is the key of a good survival of the implants. To guide the blade of the saw, cutting guides are used. The position of these guides gives the final position of the cuts. At present, two main techniques are used to position the guides: the conventional one, not very costly but not very accurate, and the navigated procedure, which is more accurate but also more expensive and more invasive. Since few years, patient specific cutting guides are used in total knee replacement with encouraging results and more recently in uni compartmental knee replacement with no scientific proof of efficiency.

This study aims to validate the procedure of patient specific cutting guides.

30 patients will be included in a mono centric, single-arm study with evaluation of the primary outcome by an independent expert comity. Each participant will have an MRI which will be sent to the society in charge of creating the patient specific cutting guides. The intervention will be performed using the patient specific cutting guides and in parallel, a station of navigation will be used to provide a safety control of the orientation of the cutting guide and to collect per operative data.

Evaluation visit is performed 6 months after surgery.

Eligibility Criteria:
Inclusion Criteria:

* patients aged 18 or older;
* indication of medial unicompartmental knee replacement (validated by the orthopedic surgeons staff) ;
* written informed consent.

Exclusion Criteria:

* MRI contraindication ;
* Absence of the main investigator or the associated scientist during the surgical procedure ;
* Adults under legal protective regimen or deprived of liberty.
Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction


Eligibility Criteria:
Inclusion Criteria:

* Male patients and postmenopausal women
* Mildly/moderately decreased heart function
* Regular heart rhythm

Exclusion Criteria:

* Potassium outside normal reference values
* Child bearing potential
* Severely decreased heart function
Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older

This study evaluates the safety of Quadrivalent Influenza Virus Vaccine in Healthy People Aged years 3 to 60.40 Subjects will be equally divided into 2 groups,including 3-17 years old and 18-60 years old.Adult group first receive one dose of Quadrivalent Influenza Virus Vaccine.Then minors group also receive one dose of Quadrivalent Influenza Virus Vaccine after 7 days.


Eligibility Criteria:
Inclusion Criteria:

* healthy subjects more than 3 years old, and the subjects can be informed consent, and sign the informed consent.
* the subjects and his guardians can obey the demands of the scheme .
* Axillary temperature less than 37℃

Exclusion Criteria:

* The people who has a vaccine allergies, or who allergic to any kind of composition in experimental vaccine, such as eggs,ovalbumin etc.
* The people who has serious side effects to vaccine, such as allergy,urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain.
* the subject who has symptoms of acute infection within a week.
* Autoimmune diseases or Immune function defect, people has immunosuppressive therapy, cytotoxic treatment or inhaled corticosteroids in the past 6 months.
* People has congenital malformations, developmental disorder or serious chronic diseases( such as Down's syndrome, diabetes, Sickle cell anemia or nerve system disease)
* People has asthma Unstable that need emergency treatment, hospitalization, intubation, oral or intravenous corticosteroid in the past 2 years.
* Diagnosed abnormal coagulation(Lack of clotting factors,Clotting disorders,Platelet abnormality) or significant bruising or coagulopathy
* people has history or family history of convulsions, seizures, encephalopathy and psychiatric.
* alienia, functional asplenia, and alienia or splenectomy in any situation.
* Serious neurological disorders such as Green Barry syndrome.
* people who has received blood products or immunoglobulin products in the past one months.
* people who has received other study drug in the past one month.
* people who received live attenuated vaccine, subunit vaccine or inactivated vaccine.
* people who has received allergy treatment in in the past 14 days.
* People who is on anti-TB treatment.
* People whose axillary temperature is more than 37℃ before the vaccination.
* People who is pregnant.
* Any factors unsuitable for clinical trail according to the researchers.
Trial to Compare the Effectiveness of Group Versus Individual Therapy on Alternate Days in Patients With Subacromial Impingement Syndrome

Pathology of the rotator cuff and subacromial bursa is considered to be the principal cause of pain and symptoms arising from the shoulder. Physiotherapy specialists often disagree about which type of exercise is most appropriate. Manual Physiotherapy combined with guided exercise is a commonly applied clinical treatment, but no proof of its effectiveness has been shown. Clinical trials comparing results of treating subacromial syndrome of the shoulder with guided self-treatment and conventional physiotherapy yielded a slightly higher improvement, basically because patients suffered from chronic tendinitis and the treatment period lasted only two weeks. That is the reason why the investigators propose a long-term follow-up study and a more complete assessment of effectiveness of the exercise prescribed to improved this pathology.

Objectives:

* Assessment of effectiveness of two different types of treatment of subacromial syndrome of the shoulder.
* Comparison of effectiveness of both treatments in order to select that one yielding better results as the one to be applied as a routine practice.

Patients will be assigned one of the following treatments:

* Group 1: patients will be taught exercises in groups of six people, on a daily basis for twelve sessions.
* Group 2: patients will be taught the same exercise as Group 1, individually, and will receive manual therapy consisting of muscular and joint re-centering.

A modified version of the Constant scale will be used to assess mobility and pain shoulder.


Eligibility Criteria:
Inclusion Criteria:

* History of shoulder pain defined as at least 2 positive results in subacromial impingement tests.
* Self-perceived pain reported by the patient under clinical examination of the shoulder.
* A minimum of 90º mobility in flexion.

Exclusion Criteria:

* Luxation, a history of surgery, or evidence the current shoulder pain or other symptoms under cervical examination or other shoulder bone disease, except for acromioclavicular joint arthrosis.
* Patients were receiving other physiotherapy or rehabilitation treatments.
* Patients had been treated for SIS (subacromial impingement syndrome) with injection of anti-inflammatory or analgesic drugs in the last month.
Changes in Physical, Cognitive and Emotional Function 5 and 10 Years After Aneurysmal Subarachnoid Hemorrhage (aSAH)

The current study is a continuation of the study "Effect of early rehabilitation in patients with acute aSAH" which was approved by the Regional Committee for Medical Research Ethics, South-East Norway, archive number 2011/2189, Clinical Trials number 0925-0586 (Clinical Trials gov. identifier NCT01656317). The original study was a prospective, controlled, interventional study comprising patients managed at the neuro-intermediate ward following repair of a ruptured intracranial aneurysm in 2011-2012. 157 patients signed the informed consent form and were included in the study. Patients were assessed in the acute phase, as well as a 3 and 12 months post ictus. The main research goal of the present study will be to assess physical, cognitive and emotional function 5 and 10 years after aSAH in the 2011-2012 population. In addition we will also describe quality of life and work-status along with the time-course of recovery from the acute sage after aSAH to the chronic phase.


Eligibility Criteria:
Inclusion Criteria:

* Patients with aSAH treated at Oslo University Hospital in 2011-2012
* Only patients with signed informed consent form and thereby included the project "Effect of early rehabilitation in patients with acute subarachnoid hemorrhage" (Regional Committee for Medical Research Ethics, South-East Norway, archive number 2011/2189, Clinical Trials number 0925-0586, Clinical Trials gov. identifier NCT01656317) will be asked to participate.

Exclusion criteria:

* Patients with aSAH treated at Oslo University Hospital in 2011-2012 who did not sign an informed consent form in the project "Effect of early rehabilitation in patients with acute subarachnoid hemorrhage" (Regional Committee for Medical Research Ethics, South-East Norway, archive number 2011/2189, Clinical Trials number 0925-0586, Clinical Trials gov. identifier NCT01656317)
Vascular Cell Activation, Cell-Derived Microparticles and In Vitro Fertilisation, and In Vitro Fertilisation

Introduction: Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic phenomenon, poorly understood and difficult to predict, complicating intense ovarian stimulation cycle. The most severe symptoms, which associate vascular permeability disorders and hypercoagulability, occur in 0.2 to 1% of the cases and often require intensive care.

Activation of endothelial, platelet, erythrocyte or leukocyte cells trigger the release of small specific vesicles, called microparticles, used as markers.

Classically leading to endothelial dysfunction and hypercoagulability, the endothelial activation phenomenon could constitute the main cause of OHSS or help predict its severity, as established for various other diseases (cerebral stroke, infarct and lupus...). However, so far, this endothelial activation role has never been studied.

Objectives:

Evaluate the serum level of microparticles as a predictor of adverse outcomes; correlate it to hypercoagulability and changes of endothelial permeability associated with this syndrome.

Methodology: Prospective Pilote Cohort study, evaluating before and throughout the ovarian stimulation cycle (6 samples/patient), the serum modulation of:

* Endothelial activation markers (endothelial-derived microparticles, E-selectin)
* Procoagulant markers (microparticles from platelet, erythrocyte or leukocyte origin, Von Willbrand factor, thrombin-antithrombin complex, prothrombin fragment 1+2)
* Endothelial disjunction marker (soluble CD 146) A group of 50 patients will be assessed Techniques: Flow cytometry for measurement of microparticles expressing non specific (Annexin V) and cell specific surface determinants (CD 31, CD 41, CD 45 or glycophorin A). Use of commercial kits for other serum markers.


Eligibility Criteria:
Inclusion Criteria:

* Between 18 and 35 years old
* With Health Insurance
* Scheduled for their first ovarian stimulation in an IVF or ICSI program in our centre
* Whose blood samples will be collected in our hospital

Exclusion Criteria:

* Suffering or having suffered from a disease likely to alter their vascular system and thus modulate their rates of microparticles:

  * auto-immune disease (systemic lupus erythematosus26, antiphospholipid syndrome)
  * cardiovascular risk factors: cardiovascular disease history, diabetes, arterial hypertension, dyslipidemia
  * Tobacco addiction.
* Presenting a blood œstradiol rate \> 5000 pg/ml at ovulation triggering (criterion of stimulation cancellation) and more generally, every patient which ovulation has not been triggered.
Individual Cerebral Hemodynamic Oxygenation Relationships (ICHOR 1)

This is an observational study in patients who require clinical anesthesia. The main purpose of this study is to understand whether there are differences in the cerebral blood flow, and oxygen metabolism affected by different types of anesthesia. Subjects who require clinical anesthesia for a clinical MRI and for whom the use of anesthetics for the exam are in clinical equipoise are asked to join the study. All eligible subjects will be asked to provide informed consent before participating in the study.

This is an observational study in patients who require clinical anesthesia. The main purpose of this study is to understand whether there are differences in the cerebral blood flow, and oxygen metabolism affected by different types of anesthesia. Subjects who require clinical anesthesia for a clinical MRI and for whom the use of anesthetics for the exam are in clinical equipoise are asked to join the study. All eligible subjects will be asked to provide informed consent before participating in the study.

Treatment:

Those who meet eligibility criteria, and who undergo the informed consent, will have their MRI extended by up to 7.5 minutes for up to 5 times. Standard-of-care anesthesia safety, dose and monitoring will not be changed. During their MRI, the additional images acquired will teach us about cerebral blood flow and cerebral venous oxygenation. Participants will also have non-invasive monitoring of their hematocrit immediately following the exam.

Safety Assessment:

The experiment will occur in the standard-of-care clinical MRI environment. All patient safety and monitoring will remain in place. Throughout the induction, maintenance and recovery from anesthesia, all procedures will occur in the standard of care environment and will be overseen by trained clinical personnel.

Efficacy Assessment:

Structural, and/or cerebral blood flow and/or metabolism MRIs will be collected from all subjects.

Eligibility Criteria:
Inclusion Criteria:

* Individuals who are able to tolerate an MRI.
* Are patients scheduled for a clinically indicated MRI.
* Between birth and up to 18 years.

Exclusion Criteria:

* Presence of an MRI-incompatible device or implant (e.g. pacemakers, stents)
* Unable to tolerate the enclosed spaces and loud noises for the duration of time in scanner required to obtain an MRI.
* Preterm infants less than 25 weeks
* Any patient who is clinically too unstable to extend their MRI by up-to 7.5 minutes.
Nutritional Supplementation in Adults With Chronic Respiratory Disease

The purpose of this study is to determine whether nutritional support with a complete formula is effective to improve malnutrition and respiratory function in patients with chronic pulmonary disease compared to the standard hospital dietary advise.

This is a unicenter, controlled, randomized, prospective, parallel-group, open-label study to evaluate the effect of a nutritional formula on nutritional status, pulmonary function and quality of life. Adult patients will be randomized to receive the nutritional formula or to follow the standard hospital' dietetic recommendations during 12 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged between 18 and 80 years.
* Patient from Clínica San Gabriel or Clínica San Pablo Surco, inpatient or outpatient.
* Patients with chronic pulmonary disease (including bronchiectasis, tuberculosis specific sequel, fibrothorax, diffuse interstitial lung disease, COPD).
* Patients presenting one or more of the following situations of malnutrition or nutritional risk: BMI \<21 kg/m2 (or\<23 kg/m2 in patients ≥ 65); unintentional weight loss \>10% in the past 6 months; unintentional weight loss \>5% in last moth; FFMI \<15 kg/m2 (women) or \<16 kg/m2 (men).
* Patients who signed informed consent.

Exclusion Criteria:

* Clinically unstable patients.
* Patients requiring other nutritional supplements or parenteral nutrition.
* Patients diagnosed with active pulmonary tuberculosis.
* Patients with acute respiratory failure.
* Patients with immunosuppression (including HIV, diabetes or neoplasms).
RISK FACTOR ANALYSIS OF CHEWING AND SWALLOWING PERFORMANCE IN GERIATRICS

Various structural and functional problems in neural, sensory and perceptual, cardiovascular, pulmonary, gastrointestinal, endocrine, and musculoskeletal systems occur in geriatrics not associated with a specific disease. One of the problems observed in geriatrics is chewing and swallowing disorders. Failure to detect changes in chewing and swallowing performance in elderly individuals at an early stage may lead to chewing and swallowing disorders and serious complications in later stages. Therefore, it is necessary to comprehensively and systematically address the possible factors affecting chewing and swallowing performance in geriatric individuals.

The first aim of the study is to analyze the factors affecting chewing and swallowing performance in geriatric individuals within the scope of the International Classification of Functioning, Disability, and Health (ICF). The second aim of the study is to create a dysphagia risk prediction model for geriatric individuals based on the results of the analyses to be conducted.

In the study, the dependent variables, chewing performance, will be evaluated with the Chewing and Swallowing Test of Solids, and swallowing performance will be assessed with the Repetitive Saliva Swallowing Test and Dysphagia Limit. Independent variables affecting chewing and swallowing performance have been considered within the scope of the ICF, and all possible factors determined for both geriatrics and swallowing have been listed, and the evaluation parameters and assessment tools have been decided. The evaluation parameters have been categorized under ICF headings such as personal factors, body structures, body functions, activity and participation, and environmental factors, and the evaluations to be conducted have been divided into two groups: geriatric and physiotherapy evaluations. The geriatric evaluations are part of routine geriatric assessment and do not include any specific evaluation for the study. Physiotherapy evaluations will be applied in a certain order to use time efficiently and will take approximately 35-45 minutes. Through geriatric and physiotherapy evaluations, a holistic assessment of participants within the scope of ICF will be ensured.


Eligibility Criteria:
Inclusion Criteria:

* being voluntary to participation,
* Being over 65 years old,
* Understanding and following simple instructions,
* Being able to walk independently for 4 meters.

Exclusion Criteria:

* Having a problem that prevents communication and/or following simple instructions.
Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract

The present monocentric prospective phase 2 study aims to reproduce the results obtained at NIRS thus offering the possibility of obtaining a promising rate of progression-free survival (PFS) and local control (LC) in patients diagnosed with mucosal melanoma of lower genital tract. Systemic treatment with immunotherapy is not the subject of this study but is allowed both in the neoadjuvant and sequential regimens.

Melanomas have always been considered poorly radiosensitive. It is now accepted that high LET (Linear Energy Transfer) particle beams, such as carbon ions, can offer a biological advantage, compared to photons treatment, in radio-resistant neoplasms treatment, thanks to their higher biological efficacy (RBE) against tumours with a low α/ ß ratio. In addition, carbon ions have the physical advantage of an inverted depth deposition profile compared to photons, allowing then a steep dose gradients that ensure increased sparing of adjacent healthy organs at risk (OARs).

Patients with primary gynaecological melanoma, non-metastatic, non-suitable for surgery, and not previously subjected to conventional radiotherapy can be enrolled in the trial, according to selection criteria. After requested baseline exams, the patient undergoes to simulation phase for the carbon ion radiation therapy, according to study constraints. The patient will then receive immunotherapy not concomitant to CIRT. The response is evaluated through RECIST criteria.

PFS is the primary endpoint, calculated from the end of CIRT to date of disease progression or death or last follow up.

Eligibility Criteria:
Inclusion Criteria:

* Histological diagnosis
* Absence of skin extension
* N + (only if confined to the groin and pelvis)
* Age between 20-80 years
* ECOG 0-2
* No evidence of metastasis
* At least 5 mm away with rectum and bladder wall
* No previous RT
* Written informed consent
* Patient's ability to understand the characteristics and consequences of the clinical trial
* Molecular characterization/ mutational state
* Disease staging (baseline exams)

Exclusion Criteria:

* Hip prosthesis, or metal prostheses or any other condition that prevents adequate imaging to identify the target volume and calculate the dose in the treatment plan
* Psychic or other disorders that may prevent informed consent
* Previous invasive tumor unless patient has been disease free for at least 3 years
* Contraindication to MRI
* Pregnancy or breastfeeding in progress